Island Pharmaceuticals Limited (ILA.AX)
AUD 0.18
(2.94%)
AUD 0.18
(2.94%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -2.81 Million AUD | 0.0% |
| 2023 | - AUD | -3.53% |
| 2022 | - AUD | -31.33% |
| 2021 | - AUD | 0.0% |
| 2020 | - AUD | 0.0% |
| 2019 | - AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 FY | - AUD | -41.86% |
| 2024 Q4 | -1.99 Million AUD | 0.0% |
| 2024 Q2 | -2.13 Million AUD | 0.0% |
| 2024 Q3 | -495.88 Thousand AUD | 100.0% |
| 2024 Q1 | 8715.00 AUD | 100.0% |
| 2023 Q2 | -1.63 Million AUD | -12438.51% |
| 2023 Q1 | 13.27 Thousand AUD | 100.71% |
| 2023 FY | - AUD | -3.53% |
| 2023 Q4 | -1.27 Million AUD | -6442.0% |
| 2023 Q3 | 20.03 Thousand AUD | 101.22% |
| 2022 Q3 | 56.65 Thousand AUD | 106.06% |
| 2022 Q4 | -1.87 Million AUD | -3407.82% |
| 2022 FY | - AUD | -31.33% |
| 2022 Q2 | -934.82 Thousand AUD | -2205.45% |
| 2022 Q1 | 44.4 Thousand AUD | 102.08% |
| 2021 Q1 | - AUD | 0.0% |
| 2021 FY | - AUD | 0.0% |
| 2021 Q4 | -2.13 Million AUD | -35197.8% |
| 2021 Q3 | 6094.00 AUD | 0.0% |
| 2021 Q2 | - AUD | 0.0% |
| 2020 FY | - AUD | 0.0% |
| 2019 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 10.37 Million AUD | 127.161% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -93.464% |
| Zelira Therapeutics Limited | -36.44 Million AUD | 92.267% |
| Biome Australia Limited | -1.57 Million AUD | -78.559% |
| Patrys Limited | -3.49 Million AUD | 19.301% |
| Orthocell Limited | -11.68 Million AUD | 75.875% |
| Imugene Limited | -147.97 Million AUD | 98.096% |
| Noxopharm Limited | -5.94 Million AUD | 52.601% |
| PYC Therapeutics Limited | -38.11 Million AUD | 92.607% |
| Chimeric Therapeutics Limited | -11.29 Million AUD | 75.06% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 60.782% |
| Proteomics International Laboratories Limited | -7.88 Million AUD | 64.27% |
| Cynata Therapeutics Limited | -9.95 Million AUD | 71.678% |
| CSL Limited | 4.73 Billion AUD | 100.06% |
| Arovella Therapeutics Limited | -8.83 Million AUD | 68.096% |
| Bio-Gene Technology Limited | -2.97 Million AUD | 5.273% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 105.434% |
| Starpharma Holdings Limited | -12.57 Million AUD | 77.593% |
| Nanollose Limited | -1.14 Million AUD | -145.502% |
| Memphasys Limited | -3.3 Million AUD | 14.802% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | -291.166% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | -56.886% |
| Amplia Therapeutics Limited | -4.55 Million AUD | 38.194% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | 79.754% |
| Race Oncology Limited | -14.2 Million AUD | 80.159% |
| Nyrada Inc. | -4.59 Million AUD | 38.686% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | 112.271% |
| Dimerix Limited | -24.95 Million AUD | 88.709% |
| PharmAust Limited | -9.45 Million AUD | 70.184% |
| Immutep Limited | -42.87 Million AUD | 93.427% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 93.688% |
| Alterity Therapeutics Limited | -19.57 Million AUD | 85.601% |
| BTC Health Limited | 1.05 Million AUD | 367.047% |
| Acrux Limited | -7.93 Million AUD | 64.467% |
| Neuren Pharmaceuticals Limited | 199.26 Million AUD | 101.414% |
| Biotron Limited | -5.04 Million AUD | 44.086% |
| Tissue Repair Ltd | -5.77 Million AUD | 51.201% |
| AdAlta Limited | -5.3 Million AUD | 46.855% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | 93.789% |
| Hexima Limited | -995.54 Thousand AUD | -183.073% |
| AnteoTech Limited | -11.57 Million AUD | 75.645% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 95.633% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | 86.803% |
| Avecho Biotechnology Limited | -3.24 Million AUD | 13.088% |
| Actinogen Medical Limited | -12.92 Million AUD | 78.19% |
| Immuron Limited | -6.19 Million AUD | 54.49% |
| Argenica Therapeutics Limited | -1.89 Million AUD | -48.51% |